Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19591020 | 0.81 | GRM4 (0.43) | GRM4CDK2DYRK1B | |
| SCHEMBL15646531 | 0.79 | MPO (0.36) | GRM4GRIN1GRIN2BLMNAKDM4E | |
| SCHEMBL18459225 | 0.79 | CHRNB2 (0.43) | — | |
| SCHEMBL18459205 | 0.73 | L3MBTL1 (0.53) | LMNAKDM4E | |
| SCHEMBL30481675 | 0.73 | — | — | |
| SCHEMBL805491 | 0.73 | — | — | |
| SCHEMBL19121623 | 0.72 | NOS1 (0.46) | GRM4GRIN1GRIN2BLMNAKDM4E | |
| SCHEMBL883723 | 0.72 | KDM4E (0.35) | GRM4GRIN1GRIN2BLMNAKDM4E | |
| SCHEMBL15867642 | 0.72 | NOS3 (0.40) | GRM4GRIN1GRIN2BKDM4EAAK1 | |
| SCHEMBL19591019 | 0.72 | HRH3 (0.46) | GRM4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981900-B2 | Spiro compound and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | S1PR1, S1PR2, S1PR3 | GRM4 1437/4885GRIN1 1674/4885GRIN2B 2104/4885 |
| US-10981900-B2 | Spiro compound and use thereof | S1PR1, S1PR2, S1PR3 | GRM4 1437/4885GRIN1 1674/4885GRIN2B 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.